Incyclix Bio
PrivateLast Round
Series B
Extension
Apr 8, 2026
Total Funding Raised
$52.25M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Incyclix Bio operates in Healthcare & Life Sciences and is based in Durham, North Carolina. Its latest recorded funding round was a Series B Extension round in April 2026.
Incyclix Bio is a biotechnology company that develops small molecule inhibitors of cyclin-dependent kinases (CDKs) to treat patients with advanced and resistant cancers.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Incyclix Bio Comparables
Compare Incyclix Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Avenzo Therapeutics | 91% | |
| Pyxa Pharmaceuticals | 83% | |
| Carrick Therapeutics | 83% |
For institutional investors. Book with your work email.
Incyclix Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | Apr 8, 2026 | ||||
| Series B Extension | Aug 25, 2025 | ||||
| Series B | Mar 31, 2022 | ||||
| Seed | Aug 5, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Incyclix Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| RA Capital Management | Series B, Series B Extension |
| Boxer Capital | Series B Extension, Series B |
| Hatteras Venture Partners | Series B, Series B Extension |
| Eshelman Ventures | Series B, Series B Extension, Seed |
| Cape Fear BioCapital | Series B, Series B Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 72% MoM.
- Jul 20, 2026
Open roles increased from 0 to 4, representing 31% of headcount.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- receives_financingOct 7, 2026
Incyclix Bio, LLC has raised $52M to advance precision treatments for breast and ovarian tumors, which are in active clinical trials, in North Carolina.
For institutional investors. Book with your work email.
Incyclix Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Incyclix Bio's valuation, stock price, and market status.
Is Incyclix Bio a public or private company?
Incyclix Bio is a private company.
What is the current stock price of Incyclix Bio?
Incyclix Bio is a private company, so its shares have no public market price. Caplight tracks Incyclix Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Incyclix Bio worth (valuation)?
Valuation information for Incyclix Bio is not publicly available.
Can I buy Incyclix Bio stock?
Incyclix Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Incyclix Bio's last funding round?
Incyclix Bio's most recent funding round was Series B Extension on April 8, 2026.
Who are the main investors in Incyclix Bio?
Key investors in Incyclix Bio include Boxer Capital, Eshelman Ventures.
Will Incyclix Bio IPO soon?
No public IPO plans have been announced for Incyclix Bio.
How can I track Incyclix Bio secondary market activity?
Caplight tracks bids, offers, and trades in Incyclix Bio's shares on secondary markets.